Valsartan & Losartan Blood Pressure Medication Settlement – $15.2 Million
Aurobindo Pharma, Hetero Labs, and Vivimed Labs have agreed to pay a combined $15.2 million to settle class actions over generic blood pressure medications — valsartan, losartan, and irbesartan — that were recalled due to N-Nitrosodimethylamine (NDMA) contamination. If you purchased affected medications, you may be entitled to a pro rata cash payment for the economic cost of the recalled drugs.
Do I Qualify?
You may be eligible if:
- Consumers who purchased valsartan, losartan, or irbesartan manufactured by Aurobindo, Hetero, or Vivimed during the class period
- These are generic blood pressure and heart medications subject to widespread FDA recalls beginning in 2018 due to NDMA contamination
- This settlement covers economic loss from purchasing recalled medications — not personal injury or cancer claims
- Check SartanMedicationSettlement.com for current filing status and documentation requirements
Proof required. You may need pharmacy records, receipts, or sworn attestation depending on claim tier. Verify current requirements at SartanMedicationSettlement.com.
Claim filing closed. The deadline was June 2, 2026.
What Happened?
Beginning in 2018, the FDA and international regulators discovered that many batches of valsartan, losartan, and irbesartan — generic blood pressure medications manufactured by multiple companies — contained NDMA, a compound classified as a probable human carcinogen. The FDA ordered widespread recalls across multiple manufacturers, leaving millions of Americans who had been taking these medications daily with questions about their exposure.
Aurobindo Pharma, Hetero Labs, and Vivimed Labs were among the manufacturers whose recalled products contained NDMA contamination. Class action lawsuits alleged the companies sold medications that did not meet FDA safety standards and failed to adequately warn consumers. The combined $15.2 million settlement resolves consumer claims that class members were sold defective products that did not meet the quality standards represented on their labels.
This settlement is separate from personal injury lawsuits by people who developed cancer. It covers the economic loss — the cost of recalled medications — for anyone who purchased them during the class period, not physical injury claims.
How Much Will I Actually Get?
Eligible claimants receive a pro rata share of the $15.2 million fund based on how much they spent on affected medications during the class period and the total number of valid claims filed. Individual payments depend on purchase history and claim volume. The official claim deadline was June 2, 2026 — verify any late-filing options at SartanMedicationSettlement.com.
Last reviewed: June 23, 2026 | Information verified from court records and official settlement documents.